Company Filing History:
Years Active: 2020
Title: Edward Komin Fung: Innovator in Patient-Specific Antibody Dosing
Introduction
Edward Komin Fung is a notable inventor based in New York, NY (US). He has made significant contributions to the field of cancer treatment through his innovative approaches to antibody dosing. His work focuses on optimizing therapeutic strategies for patients with tumors, particularly in the context of colorectal cancer.
Latest Patents
Edward Komin Fung holds a patent titled "Systems and methods for determining optimum patient-specific antibody dose for tumor targeting." This patent describes a non-linear compartmental model that utilizes PET-derived data to predict the optimal therapeutic dose of cargo-carrying antibodies, such as radiolabeled antibodies. The model aims to enhance the therapeutic index by assessing antigen occupancy, residency times in both normal and malignant tissues, and the cancer-to-normal tissue therapeutic index.
Career Highlights
Edward Komin Fung is affiliated with the Memorial Sloan Kettering Cancer Center, where he applies his expertise in developing innovative cancer therapies. His work is instrumental in advancing personalized medicine, particularly in the realm of antibody-based treatments.
Collaborations
Some of his notable coworkers include Pat B Zanzonico and Sarah M Cheal, who collaborate with him in research efforts aimed at improving cancer treatment methodologies.
Conclusion
Edward Komin Fung's contributions to the field of cancer treatment through his innovative patent demonstrate his commitment to enhancing patient care. His work continues to pave the way for advancements in personalized medicine and therapeutic strategies.